ConductScience.org, home

Paper39698262

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.

Mehta D and 4 others. ACS Pharmacol Transl Sci, 2024. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies. Papers, record 39698262. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39698262

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies.
PubMed
Journal
ACS Pharmacol Transl Sci
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
3.53, provisional
iCite
Revised in PubMed
2025-11-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mehta DDevashishhttps://orcid.org/0000-0001-9840-0181
2Rajput KKajalhttps://orcid.org/0000-0001-8955-4998
3Jain DDolly
4Bajaj AAvinashhttps://orcid.org/0000-0002-1333-9316
5Dasgupta UUjjainihttps://orcid.org/0000-0002-2281-078X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References153

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125519700MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Mol Cancer Ther2015https://conductscience.org/library/papers/25519700PubMed
221482669mTORC2 is required for proliferation and survival of TSC2-null cells.Mol Cell Biol2011https://conductscience.org/library/papers/21482669PubMed
319861459MYC-induced cancer cell energy metabolism and therapeutic opportunities.Clin Cancer Res2009https://conductscience.org/library/papers/19861459PubMed
426003166The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.Oncotarget2015https://conductscience.org/library/papers/26003166PubMed
526321679Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.Cell2015https://conductscience.org/library/papers/26321679PubMed
626170313Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.Proc Natl Acad Sci U S A2015https://conductscience.org/library/papers/26170313PubMed
721430067mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.Cancer Res2011https://conductscience.org/library/papers/21430067PubMed
823636326mTOR kinase structure, mechanism and regulation.Nature2013https://conductscience.org/library/papers/23636326PubMed
922500797mTOR signaling in growth control and disease.Cell2012https://conductscience.org/library/papers/22500797PubMed
1021339740Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.Oncogene2011https://conductscience.org/library/papers/21339740PubMed
1127713169A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors.Oncotarget2016https://conductscience.org/library/papers/27713169PubMed
1210691731Loss of PTEN facilitates HIF-1-mediated gene expression.Genes Dev2000https://conductscience.org/library/papers/10691731PubMed
1327174914p70S6K promotes IL-6-induced epithelial-mesenchymal transition and metastasis of head and neck squamous cell carcinoma.Oncotarget2016https://conductscience.org/library/papers/27174914PubMed
1418042549Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1.J Biol Chem2008https://conductscience.org/library/papers/18042549PubMed
1524140020mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.Cell Metab2013https://conductscience.org/library/papers/24140020PubMed
1622067397Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.J Clin Oncol2012https://conductscience.org/library/papers/22067397PubMed
1719963096Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations.Semin Oncol2009https://conductscience.org/library/papers/19963096PubMed
1818089801mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor.Cancer Res2007https://conductscience.org/library/papers/18089801PubMed
1916569767Differential regulation of T-cell growth by IL-2 and IL-15.Blood2006https://conductscience.org/library/papers/16569767PubMed
2026299952Toward rapamycin analog (rapalog)-based precision cancer therapy.Acta Pharmacol Sin2015https://conductscience.org/library/papers/26299952PubMed

See all 153 referencesDownload CSV of references

Cited by17

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
42619501Astragaloside IV and rapamycin co-loaded bone marrow mesenchymal stem cell-derived exosome nanocarriers for targeted modulation of the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Nanomedicine (Lond)2026https://conductscience.org/library/papers/42619501PubMed
42305219Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.ACS Med Chem Lett2026https://conductscience.org/library/papers/42305219PubMed
42168745Polyploidy and Senescence of Cancer Cells: Impact of Cell Fusion.Adv Exp Med Biol2026https://conductscience.org/library/papers/42168745PubMed
42080921Prognostic significance of RICTOR mutations in EGFR-mutant metastatic lung adenocarcinoma: a retrospective cohort study.Virchows Arch2026https://conductscience.org/library/papers/42080921PubMed
41958649P62 in colorectal cancer: from inflammation suppression to cancer promotion.Front Immunol2026https://conductscience.org/library/papers/41958649PubMed
41424791The PI3K/AKT/mTOR pathway in scar remodeling and keloid formation: mechanisms and therapeutic perspectives.Front Pharmacol2025https://conductscience.org/library/papers/41424791PubMed
41384305mTOR in radiotherapy of lung cancer: Mechanisms of radiation resistance and therapeutic implications (Review).Int J Oncol2026https://conductscience.org/library/papers/41384305PubMed
41340489Androsin alleviates colorectal cancer by inhibiting the PI3K/Akt-centered signaling pathway.Korean J Physiol Pharmacol2026https://conductscience.org/library/papers/41340489PubMed
41321380Epithelial-mesenchymal dynamics in cancer: Role of signalling pathways, stromal interactions and natural therapies.ADMET DMPK2025https://conductscience.org/library/papers/41321380PubMed
41230168Icariside II attenuates renal fibrosis through mTOR signaling modulation: an integrated approach combining network pharmacology, molecular dynamics, and in vitro validation.Transl Androl Urol2025https://conductscience.org/library/papers/41230168PubMed
41201553Molecular co-alteration patterns of RICTOR-mutant metastatic lung adenocarcinomas: a single-center cohort study.Virchows Arch2026https://conductscience.org/library/papers/41201553PubMed
41188991Engineered immune-driven theranostics for clinical cardiology.Mil Med Res2025https://conductscience.org/library/papers/41188991PubMed
41181393Circadian system and aging: where both times interact.Front Aging2025https://conductscience.org/library/papers/41181393PubMed
40996472Synthesis of CNP-SAR405 delivery system for improved therapeutics anticancer activity using A549 human lung cancer cell lines.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/40996472PubMed
40671967A comprehensive analysis of the relationship between inflammasomes and autophagy in human tumors: Recent developments.J Cell Commun Signal2025https://conductscience.org/library/papers/40671967PubMed
40148397An in- vitro measurement for the toxicity of peptides inhibit hexokinase II in breast cancer cell lines.Sci Rep2025https://conductscience.org/library/papers/40148397PubMed
40092733IL-11 promotes Ang II-induced autophagy inhibition and mitochondrial dysfunction in atrial fibroblasts.Open Life Sci2025https://conductscience.org/library/papers/40092733PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39698262

GET https://conductscience.org/api/papers/v1/39698262/references?page=2